Igm Biosciences Inc (IGMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2022 | 09-2022 | 06-2022 | 03-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -221,102 | -168,526 | -110,489 | -51,894 | -165,164 |
| Depreciation Amortization | 3,362 | 3,451 | 2,862 | 1,389 | 5,108 |
| Accounts payable and accrued liabilities | -3,002 | -2,570 | -2,051 | -1,244 | 652 |
| Other Working Capital | 155,170 | 156,843 | 153,519 | -864 | 6,447 |
| Other Operating Activity | 59,719 | 42,807 | 28,577 | 13,724 | 27,975 |
| Operating Cash Flow | $-5,853 | $32,005 | $72,418 | $-38,889 | $-124,982 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -10,206 | -7,511 | -4,800 | -2,977 | -13,244 |
| Purchase Of Investment | -540,022 | -381,629 | -282,512 | -40,126 | -128,705 |
| Sale Of Investment | 324,584 | 182,307 | 84,227 | 24,000 | 157,410 |
| Investing Cash Flow | $-225,644 | $-206,833 | $-203,085 | $-19,103 | $15,461 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 219,382 | 218,900 | 218,603 | 133 | 4,031 |
| Other Financing Activity | 0 | 0 | 0 | -61 | -1,555 |
| Financing Cash Flow | $219,382 | $218,900 | $218,603 | $72 | $2,476 |
| Beginning Cash Position | 134,035 | 134,035 | 134,035 | 134,035 | 241,080 |
| End Cash Position | 121,920 | 178,107 | 221,971 | 76,115 | 134,035 |
| Net Cash Flow | $-12,115 | $44,072 | $87,936 | $-57,920 | $-107,045 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,853 | 32,005 | 72,418 | -38,889 | -124,982 |
| Capital Expenditure | -10,206 | -7,511 | -4,800 | -2,977 | -13,244 |
| Free Cash Flow | -16,059 | 24,494 | 67,618 | -41,866 | -138,226 |